Zamanian, Atefeh
Rousseau, Étienne
Buteau, François-Alexandre
Arsenault, Frédéric
Beaulieu, Alexis
April, Geneviève
Juneau, Daniel
Plouznikoff, Nicolas
Turcotte, Éric E.
Allard, Catherine
Richard, Patrick O.
Saad, Fred
Guérin, Brigitte
Pouliot, Frédéric
Beauregard, Jean-Mathieu
Funding for this research was provided by:
Fonds de recherche du Québec–Santé’s Clinical Research Scholars awards.
Oncopole EMC2, a peer-reviewed funding grant that matched unrestricted funds from the Fonds de Recherche du Québec–Santé public agency, the Cancer Research Society, and Merck Canada.
Article History
Received: 22 May 2025
Accepted: 8 July 2025
First Online: 15 July 2025
Declarations
:
: This study was conducted in compliance with the declaration of Helsinki and received authorization from the central research ethic board and all participants provided written informed consent prior to their inclusion in the study.
: Not applicable.
: Senior authors J.M.B. and F.P. have received consultancy honoraria from, and are local principal investigators for, Novartis. J.M.B. is a local principal investigator for Point Biopharma.